Buscar
Congreso SOLACI
HomeStructural heart diseaseValvular Aortic Valve

Valvular Aortic Valve

Ver Categoría

Mitral valve

TCT 2024 | TRISCEND II: A New Hope in Percutaneous Tricuspid Valve Replacement

Advanced tricuspid regurgitation (TR) is a debilitating disease associated with heart failure and increased mortality.  Edge-to-edge repair has...
Dr. Carlos Fava -
Ver más
Structural Heart Disease

TCT 2024 – TAVR UNLOAD: Moderate Aortic Stenosis with Ventricular Function Deterioration

The prevalence of aortic stenosis (AS) is on the rise in developed countries, and the link between...
Dr. Carlos Fava -
Ver más
Coronary disease

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation...
Dr. Carlos Fava -
Ver más
Antithrombotic Anticoagulants

TAVR and Atrial Fibrillation: What Anticoagulants Should We Use?

The prevalence of atrial fibrillation (AF) in TAVR patients ranges from 15 to 30%, depending on series....
Dr. Carlos Fava -
Ver más
Structural heart disease

ENVISAGE-TAVI AF Trial: What Anticoagulant Should We Use?

Between 15% and 30% of patients undergoing TAVR present atrial fibrillation. Many of them have suffered ischemic...
Dr. Carlos Fava -
Ver más
Mitral valve

Evolution at 1 Year for the PARTNER 3 Mitral Valve-in-Valve Study

At present, the structural failure of mitral bioprostheses due to their deterioration poses a significant challenge. While...
Dr. Carlos Fava -
Ver más
Antithrombotic Anticoagulants

Should We Withdraw Anticoagulation Before TAVR?

Approximately one-third of patients undergoing transcatheter aortic valve replacement (TAVR) have atrial fibrillation and are on oral...
Dr. Carlos Fava -
Ver más
Coronary disease

¿What Should We Do About Significant Coronary Lesions in TAVR?

Aortic stenosis and coronary artery disease (CAD) share risk factors, which means significant lesions will coexist in...
Dr. Carlos Fava -
Ver más

SOLACI es la organización de referencia del intervencionismo cardiovascular latinoamericano.

Últimas Noticias

1-Year Outcomes of US TAVR Registry with 5th Generation Balloon Expandable Valves

Dr. Andrés Rodríguez - 0
The use of transcatheter aortic valve replacement (TAVR) has extended to younger patients with lower risk severe aortic stenosis (AS) and therefore the improvement...

EuroSMR Registry: Edge-to-Edge Mitral Treatment with 5-Year Outcomes

Dr. Carlos Fava - 0
Cardiomyopathies and left atrial enlargement can lead to secondary mitral regurgitation (SMR). This condition is associated with ventricular dysfunction, causing heart failure, hospitalization, and...

TricValve Transcatheter Bicaval Valve System for Severe Tricuspid Insufficiency: Events at One Year

Dr. Omar Tupayachi - 0
TricValve is the first bicaval valve system to obtain CE-Mark approval. This device heterotopic device eliminates tricuspid insufficiency reflux into the venous system, reducing...

Noticias Institucionales

Hemodynamics and Interventional Cardioangiology Hybrid Training Course SOLACI-CACI

solaci - 0
We are now open for registration to the hybrid training course on Hemodynamics and Interventional Cardioangiology for Technicians and Nurses SOLACI-CACI 2025 Find all course...

Check out the best images of the El Salvador 2024 Sessions

solaci - 0
Review the highlights of the XLIX SOLACI Regional Sessions held at the Intercontinental Hotel in San Salvador, El Salvador between November 7 and 8,...

The El Salvador 2024 Sessions are coming soon

solaci - 0
The XLIX SOLACI 2024 Regional Sessions (17th Central America & the Caribbean) are approaching, and will take place in the city of San Salvador (El Salvador)....

Accesos

Adolfo Alsina 2653 · Piso 2H · CABA · Buenos Aires · Argentina · (5411) 4954 7173 · info@solaci.org · solaci.org · Términos de uso -Políticas de privacidad